Clinical observation on modified Shengjiang San(升降散)in the treatment of 40 cases of pediatric herpangina with excess heat in the heart and spleen pattern
Objective To observe the clinical efficacy of modified Shengjiang San(升降散)in the treatment of pediatric herpangina with excess heat in the heart and spleen pattern.Methods A total of 80 pediatric patients with herpangina of excess heat in the heart and spleen pattern admitted to the Pediatric Department of Zhumadian Traditional Chinese Medicine Hospital from December 2022 to May 2023 were selected and randomly divided into a treatment group and a control group using a random number table,with 40 patients in each group.The control group was treated with ribavirin spray,while the treatment group was treated with modified Shengjiang San.Both groups were treated for 5 days as one course of treatment.After one consecutive course of treatment,the clinical efficacy was evaluated,and comparisons were made in terms of changes in traditional Chinese medicine(TCM)syndrome scores,serum inflammatory factor levels,and safety before and after treatment.Results The total effective rate in the treatment group was 97.50％(39/40),significantly higher than the 85.00％(34/40)in the control group.The difference between the two groups was statistically significant(P＜0.05).Before treatment,there was no statistically significant difference in TCM syndrome scores between the two groups(P＞0.05),indicating comparability.After treatment,the TCM syndrome scores of both groups decreased compared with those before treatment,with statistical-ly significant differences compared with the pre-treatment scores within the same group(P＜0.05).The decrease was more significant in the treatment group(P＜0.05).Before treatment,there were no statistically significant differences in serum levels of hs-CRP,IL-6 and TNF-α between the two groups(P＞0.05),indicating comparability.After treat-ment,the levels of these indicators decreased in both groups compared with those before treatment,with statistically significant differences compared with the pre-treatment levels within the same group(P＜0.05).The decrease was more significant in the treatment group(P＜0.05).During the treatment period,no adverse events or drug adverse reactions were observed in vital signs(temperature,blood pressure,respiration,resting heart rate),blood routine tests,urine routine tests,electrocardiograms,and liver and kidney function tests in both groups.Conclusion Modi-fied Shengjiang San exhibits satisfactory clinical efficacy in the treatment of pediatric herpangina with syndrome of excess heat in heart and spleen.It can significantly reduce the TCM syndrome scores of pediatric patients,inhibit systemic inflammatory responses,and has high safety.It is worthy of clinical promotion and application.
herpanginapediatricexcess heat in the heart and spleen patternmodified Shengjiang San(升降散)clinical observation
NETL
NSTL
万方数据
